Becotatug

DB19069InvestigationalProtein Based Therapies

Becotatug is under investigation in clinical trial NCT06380348 (JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal...

Mechanism: Pharmacologically active on Epidermal growth factor receptor
Curator reviewed
Also known as: Immunoglobulin G1, anti-(human epidermal growth factor receptor) (human-Mus musculus monoclonal JMT101 γ1-chain), disulfide with human-Mus musculus monoclonal JMT101 κ-chain, dimer · Jmt101 (fully human monoclonal igg1 antibody targeting epidermal growth factor receptor (egfr))
Code names: JMT-101

Resolves to

Compound

UNII981YA69AO3CAS2648260-93-7

Targets

P00533EGFR

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

12Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Becotatug, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account